XML 15 R4.htm IDEA: XBRL DOCUMENT v3.26.1
Condensed Consolidated Statements of Operations - USD ($)
 3 Months Ended
Mar. 31, 2026
Mar. 31, 2025
Revenue:    
Total revenue $ 117,700,000 $ 84,685,000
Operating expenses:    
Research and development 21,416,000 18,524,000
Sales and marketing 30,373,000 22,991,000
General and administrative 30,484,000 22,769,000
Litigation settlement expense 600,000 5,360,000
Total operating expenses 116,502,000 98,059,000
Income (loss) from operations 1,198,000 (13,374,000)
Other income:    
Interest income, net 1,909,000 2,784,000
Other (expense) income, net (330,000) 295,000
Total other income 1,579,000 3,079,000
Income (loss) before income taxes 2,777,000 (10,295,000)
Income tax benefit (expense) 32,012 (58,000)
Net income (loss) $ 2,809,000 $ (10,353,000)
Net income (loss) per share (Note 3):    
Basic (in usd per share) $ 0.05 $ (0.19)
Diluted (in usd per share) $ 0.05 $ (0.19)
Weighted-average shares used to compute net income (loss) per share:    
Basic (in shares) 51,151,794 55,262,459
Diluted (in shares) 53,129,928 55,262,459
Testing services revenue    
Revenue:    
Total revenue $ 91,398,000 $ 61,921,000
Operating expenses:    
Cost of testing services, product, patient and digital solutions 17,097,000 15,113,000
Product revenue    
Revenue:    
Total revenue 10,346,000 10,810,000
Operating expenses:    
Cost of testing services, product, patient and digital solutions 4,834,000 5,586,000
Patient and digital solutions revenue    
Revenue:    
Total revenue 15,956,000 11,954,000
Operating expenses:    
Cost of testing services, product, patient and digital solutions $ 11,698,000 $ 7,716,000